|
An innovative biotech company |
|
U3 Pharma GmbH, based in Martinsried near Munich, Germany, is a leader in targeted cancer drug development. Established in July 2001, the company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by its founder - Professor Axel Ullrich.
In May 2008, U3 Pharma was bought by DAIICHI SANKYO Co. Ltd., one of the top 20 leading pharmaceutical companies worldwide and No. 3 in Japan. Being part of this global environment, U3 Pharma is striving to provide patients around the world with innovative antibody-based therapeutics. |
|
|
Company News
|
Professor Axel Ullrich Honored With Israeli Wolf Prize
Professor Axel Ullrich is the winner of the Wolf Prize in Medicine 2010, which is endowed with 100 000 dollar. Ullrich, director of the Department Molecular Biology at the Max Planck Institute of Biochemistry in Martinsried near Munich, receives the prize for his ground-breaking work in cancer research.
|
|
Read more...
|
|
|
Company News
|
Daiichi Sankyo Contributes to Relief Efforts
for Haitian Earthquake Victims
Tokyo, January 19, 2010 - Daiichi Sankyo Company, Limited (hereafter; Daiichi Sankyo) has announced that it will donate ¥5 million Japanese yen (approximately $54,000 US dollars) through the Japanese Red Cross to assist victims of the January 12th Haitian earthquake.
|
|
Read more...
|
|
|
